Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases

BACKGROUND: The relapsing nature of Plasmodium vivax infection is a major barrier to its control and elimination. Factors such as adequate dosing, adherence, drug quality, and pharmacogenetics can impact the effectiveness of radical cure of P. vivax and need to be adequately evaluated. CYP2D6 pathwa...

Descripción completa

Detalles Bibliográficos
Autores principales: de Pina-Costa, Anielle, Silvino, Ana Carolina Rios, dos Santos, Edwiges Motta, Pedro, Renata Saraiva, Moreira, José, Umana, Gabriela Liseth, da Silva, Ana Danielle Tavares, da Rosa Santos, Otília Helena Lupi, de Deus Henriques, Karina Medeiros, Daniel-Ribeiro, Cláudio Tadeu, Brasil, Patrícia, Sousa, Tais Nobrega, Siqueira, André M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364036/
https://www.ncbi.nlm.nih.gov/pubmed/34391426
http://dx.doi.org/10.1186/s12936-021-03869-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364036/
https://www.ncbi.nlm.nih.gov/pubmed/34391426
http://dx.doi.org/10.1186/s12936-021-03869-x

Ejemplares similares